Kyritsis AP - Search Results

1

Central and peripheral nervous system toxicity of common chemotherapeutic agents.

Sioka C, Kyritsis AP. Sioka C, et al. Among authors: kyritsis ap. Cancer Chemother Pharmacol. 2009 Apr;63(5):761-7. doi: 10.1007/s00280-008-0876-6. Epub 2008 Nov 25. Cancer Chemother Pharmacol. 2009. PMID: 19034447 Review.

2

Cauda equina paraganglioma: a review.

Miliaras GC, Kyritsis AP, Polyzoidis KS. Miliaras GC, et al. Among authors: kyritsis ap. J Neurooncol. 2003 Nov;65(2):177-90. doi: 10.1023/b:neon.0000003753.27452.20. J Neurooncol. 2003. PMID: 14686739 Review.

3

Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas.

Sioka C, Kyritsis AP. Sioka C, et al. Among authors: kyritsis ap. J Neurooncol. 2009 Mar;92(1):1-6. doi: 10.1007/s11060-008-9734-y. Epub 2008 Nov 21. J Neurooncol. 2009. PMID: 19023520 Review.

4

Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.

Dabaja BS, McLaughlin P, Ha CS, Pro B, Meyers CA, Seabrooke LF, Wilder RB, Kyritsis AP, Preti HA, Yung WK, Levin V, Cabanillas F, Cox JD. Dabaja BS, et al. Among authors: kyritsis ap. Cancer. 2003 Sep 1;98(5):1021-8. doi: 10.1002/cncr.11627. Cancer. 2003. PMID: 12942571 Free article. Clinical Trial.

5

CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.

Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WK. Kunschner LJ, et al. Among authors: kyritsis ap. Cancer Invest. 2002;20(7-8):948-54. doi: 10.1081/cnv-120005910. Cancer Invest. 2002. PMID: 12449727 Clinical Trial.

6

Difluoromethylornithine in cancer: new advances.

Alexiou GA, Lianos GD, Ragos V, Galani V, Kyritsis AP. Alexiou GA, et al. Among authors: kyritsis ap. Future Oncol. 2017 Apr;13(9):809-819. doi: 10.2217/fon-2016-0266. Epub 2017 Jan 27. Future Oncol. 2017. PMID: 28125906 Review.

7

A systematic approach to the management of patients with brain metastases of known or unknown primary site.

Kyritsis AP, Markoula S, Levin VA. Kyritsis AP, et al. Cancer Chemother Pharmacol. 2012 Jan;69(1):1-13. doi: 10.1007/s00280-011-1775-9. Epub 2011 Nov 1. Cancer Chemother Pharmacol. 2012. PMID: 22042515 Review.

8

Paraneoplastic neurological syndromes and the role of PET imaging.

Sioka C, Fotopoulos A, Kyritsis AP. Sioka C, et al. Among authors: kyritsis ap. Oncology. 2010;78(2):150-6. doi: 10.1159/000312657. Epub 2010 Apr 13. Oncology. 2010. PMID: 20389137 Review.

9

Akathisia induced by mirtazapine after 20 years of continuous treatment.

Markoula S, Konitsiotis S, Chatzistefanidis D, Lagos G, Kyritsis AP. Markoula S, et al. Among authors: kyritsis ap. Clin Neuropharmacol. 2010 Jan-Feb;33(1):50-1. doi: 10.1097/WNF.0b013e3181bf213b. Clin Neuropharmacol. 2010. PMID: 20124786

10

Gender specific association of decreased bone mineral density in patients with epilepsy.

Markoula S, Sioka C, Exarchopoulos T, Chatzistefanidis D, Kalef-Ezra J, Fotopoulos A, Kyritsis AP. Markoula S, et al. Among authors: kyritsis ap. Neurol Neurochir Pol. 2015;49(4):267-71. doi: 10.1016/j.pjnns.2015.06.007. Epub 2015 Jun 22. Neurol Neurochir Pol. 2015. PMID: 26188944

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results